Table 6.

Fisher’s exact test for AFF in univariate analysis

	Category	Incidence rate (95% CI)	p-value
All		0.018 (0.006–0.042)
Primary disease	Breast	0.025 (0.007–0.064)	0.3968
	Other	0.008 (0–0.046)
Stage at diagnosis	Stage 1–2	0.013 (0–0.069)	1
	Stage 3–4	0.014 (0.002–0.051)
Gender	Female	0.027 (0.009–0.063)	0.1713
	Male	0 (0–0.039)
Age	< 65	0.023 (0.005–0.065)	0.6716
	> = 65	0.014 (0.002–0.049)
Metastatic site: liver	No	0.03 (0.01–0.068)	0.1601
	Yes	0 (0–0.034)
Metastatic site: lung	No	0.013 (0.002–0.045)	0.6548
	Yes	0.025 (0.005–0.072)
Metastatic site: lymph node	No	0.023 (0.005–0.066)	0.669
	Yes	0.014 (0.002–0.049)
Metastatic site: femur	No	0.021 (0.007–0.049)	1
	Yes	0 (0–0.086)
Number of denosumab doses	< 10	0 (0–0.027)	0.0605
	> = 10	0.035 (0.012–0.081)
Number of denosumab doses	< 25	0.005 (0–0.025)	0.0057
	> = 25	0.074 (0.021–0.179)
Prior zoledronic acid treatment	No	0.006 (0–0.033)	0.0151
	Yes	0.071 (0.02–0.173)